{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:28:05Z","timestamp":1791127685133,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.bbr.2008.05.016","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T09:53:57Z","timestamp":1212141237000},"page":"98-102","source":"Crossref","is-referenced-by-count":145,"title":["Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?"],"prefix":"10.1016","volume":"195","author":[{"given":"Herbert Y.","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbr.2008.05.016_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1037\/0894-4105.11.3.437","article-title":"Is it possible to be schizophrenic yet neuropsychologically normal?","volume":"11","author":"Palmer","year":"1997","journal-title":"Neuropsychology"},{"issue":"1","key":"10.1016\/j.bbr.2008.05.016_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.bbr.2008.05.016_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.bbr.2008.05.016_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.bbr.2008.05.016_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2008.05.016_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1017\/S1461145705006310","article-title":"Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia","volume":"9","author":"Sumiyoshi","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib7","article-title":"A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment","author":"Harvey","year":"2007","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.bbr.2008.05.016_bib8","first-page":"31","article-title":"Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav","volume":"184","author":"Grayson","year":"2007","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.bbr.2008.05.016_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1073\/pnas.0711273105","article-title":"Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task","volume":"105","author":"Bubenikova-Valesova","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2008.05.016_bib10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT2A and D2 receptor blockade increases cortical DA release via of 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J Neurochem"},{"issue":"November 23 (47)","key":"10.1016\/j.bbr.2008.05.016_bib11","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"D\u00edaz-Mataix","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2008.05.016_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2006.12.007","article-title":"Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex","volume":"559","author":"Sato","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.bbr.2008.05.016_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.105.087163","article-title":"Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain","volume":"315","author":"Assi\u00e9","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.bbr.2008.05.016_bib14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/sj.npp.1300869","article-title":"Effects of 5-HT on memory and the hippocampus: model and data","volume":"31","author":"Meeter","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2008.05.016_bib15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","article-title":"Molecular targets for treating cognitive dysfunction in schizophrenia","volume":"33","author":"Gray","year":"2007","journal-title":"Schizophr Bull"},{"issue":"7183","key":"10.1016\/j.bbr.2008.05.016_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2008.05.016_bib17","first-page":"853","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT) (1A) receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2008.05.016_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004714-199002000-00025","article-title":"Effects of buspirone in seven schizophrenic subjects","volume":"10","author":"Brody","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004714-199106000-00008","article-title":"An open trial of buspirone added to neuroleptics in schizophrenic patients","volume":"11","author":"Goff","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00004714-200108000-00015","article-title":"An open study of buspirone augmentation of neuroleptics in patients with schizophrenia","volume":"21","author":"Sirota","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004714-198902000-00021","article-title":"Use of buspirone in the treatment of schizophrenia","volume":"9","author":"Sovner","year":"1989","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.pnpbp.2007.02.017","article-title":"Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia","volume":"31","author":"Sumiyoshi","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2008.05.016_bib24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.bjp.0706859","article-title":"Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist. F13714: a microdialysis study in the rat","volume":"149","author":"Assi\u00e9","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1381612023396483","article-title":"The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease","volume":"8","author":"Schechter","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bbr.2008.05.016_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01292618","article-title":"Effect of pindolol on hormone secretion and body temperature: partial agonist effects","volume":"103","author":"Meltzer","year":"1996","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2008.05.016_bib27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0169-328X(95)00098-D","article-title":"Chronic buspirone treatment differentially regulates 5-HT1A and 5-HT2A receptor mRNA and binding sites in various regions of the rat hippocampus.","volume":"32","author":"Chen","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"issue":"2","key":"10.1016\/j.bbr.2008.05.016_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/nlme.1998.3866","volume":"71","author":"Meneses","year":"1999","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.bbr.2008.05.016_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0197-0186(96)00124-6","article-title":"[3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia","volume":"30","author":"Burnet","year":"1997","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bbr.2008.05.016_bib30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0893-133X(96)00053-X","article-title":"5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia","volume":"15","author":"Burnet","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2008.05.016_bib31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","article-title":"Alterations in the cortical serotonergic system in schizophrenia: a postmortem study","volume":"42","author":"Gurevich","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0024-3205(91)90556-Q","article-title":"Increase in serotonin 5HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia","volume":"48","author":"Hashimoto","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.bbr.2008.05.016_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0006-3223(95)00026-7","article-title":"Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia","volume":"39","author":"Simpson","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0006-8993(95)01361-X","article-title":"Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia","volume":"708","author":"Sumiyoshi","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2008.05.016_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/15622970209150614","article-title":"Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology","volume":"3","author":"Kasper","year":"2002","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib36","first-page":"146S","article-title":"Imaging of the serotonin system in depression and schizophrenia","volume":"51","author":"Tauscher","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199210000-00009","article-title":"Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine","volume":"12","author":"Miller","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib39","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","article-title":"Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment","volume":"158","author":"Sumiyoshi","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","article-title":"The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia","volume":"49","author":"Sumiyoshi","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004714-200006000-00019","article-title":"Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia [letter]","volume":"20","author":"Sumiyoshi","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0269881107068066","article-title":"Lack of deleterious effects of buspirone on cognition in healthy male volunteers","volume":"21","author":"Chamberlain","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1176\/appi.ajp.160.2.334","article-title":"Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory","volume":"160","author":"Yasuno","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1176\/appi.ajp.161.8.1505","article-title":"Serotonin 1A receptors in memory function","volume":"161","author":"Sumiyoshi","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2008.05.016_bib45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1017\/S1461145705006310","article-title":"Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia","volume":"29","author":"Sumiyoshi","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pnpbp.2005.10.015","article-title":"Perospirone in the treatment of schizophrenia: effect on verbal memory organization","volume":"30","author":"Araki","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bbr.2008.05.016_bib48","doi-asserted-by":"crossref","unstructured":"Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY, 2007. Effect of buspirone, a serotonin(1A) partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res.","DOI":"10.1016\/j.schres.2007.06.008"},{"key":"10.1016\/j.bbr.2008.05.016_bib49","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE Schizophrenia Trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2008.05.016_bib50","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1523\/JNEUROSCI.1187-05.2005","article-title":"Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism","volume":"25","author":"Yuen","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2008.05.016_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.brainres.2005.02.072","article-title":"Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.","volume":"1043","author":"Cosi","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2008.05.016_bib52","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00213-006-0370-y","article-title":"Role of 5-HT(1A) receptors in the modulation of stress-induced lactate metabolism in the medial prefrontal cortex and basolateral amygdala","volume":"186","author":"Uehara","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"2\u20133","key":"10.1016\/j.bbr.2008.05.016_bib53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2007.06.025","article-title":"AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus","volume":"572","author":"Li","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.bbr.2008.05.016_bib54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.105.092262","article-title":"5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms","volume":"316","author":"Madjid","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.bbr.2008.05.016_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchemneu.2004.09.001","article-title":"5-HT1A receptor mRNA and immunoreactivity in the rat medial septum\/diagonal band of Broca-relationships to GABAergic and cholinergic neurons","volume":"29","author":"L\u00fcttgen","year":"2005","journal-title":"J Chem Neuroanat"},{"issue":"7","key":"10.1016\/j.bbr.2008.05.016_bib56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.neuropharm.2006.02.005","article-title":"Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus","volume":"50","author":"Schiapparelli","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2008.05.016_bib57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.107.133082","article-title":"Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)","volume":"325","author":"Hirst","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2008.05.016_bib58","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.neuropharm.2004.02.008","article-title":"SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats","volume":"46","author":"Boulay","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2008.05.016_bib59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjp.0707160","article-title":"F15063, a compound with D2\/D3 antagonist. 5-HT1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms","volume":"151","author":"Depoortere","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bbr.2008.05.016_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.npp.1301098","article-title":"SLV313 (1-(2,3-dihydro-benzo[1.4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug","volume":"32","author":"McCreary","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2008.05.016_bib61","first-page":"539","article-title":"Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics","volume":"8","author":"Newman-Tancredi","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bbr.2008.05.016_bib62","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.neuropharm.2005.05.013","article-title":"Effects of novel antipsychotics with mixed D(2) antagonist\/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat","volume":"49","author":"Bruins Slot","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2008.05.016_bib63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2008.05.016_bib64","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2008.05.016_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-003-1683-8","article-title":"Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders","volume":"174","author":"Roth","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.bbr.2008.05.016_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/pr.59.07103","article-title":"5-HT Receptor regulation of neurotransmitter release","volume":"59","author":"Fink","year":"2007","journal-title":"Pharmacol Rev"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T19:52:21Z","timestamp":1557604341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432808002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0166432808002933"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2008.05.016","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}